NR3C2 and heart failure: Drugs affecting the renin–angiotensin–aldosterone axis, such as ACE inhibitors, angiotensin receptor blockers, or mineralocorticoid receptor blockers, are used as the primary means of treatment in patients with heart failure and reduced ejection fraction, including those with DCM.